A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide.

Trial Profile

A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Cyclophosphamide (Primary) ; Pomalidomide (Primary) ; Prednisone (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Feb 2016 Planned End Date changed from 1 Jul 2013 to 1 Jul 2018 as per ClinicalTrials.gov record.
    • 21 Mar 2012 Actual patients number changed from 41 to 67 as reported by ClinicalTrials.gov.
    • 23 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top